Arezu Aliabadi-Zuckermann

Arezu Aliabadi-Zuckermann

Auto-generated profile, based on publicly available information

Arezu Aliabadi-Zuckermann

Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
PHPhilip F. Halloran
Philip F. Halloran
KMKatelynn Madill-Thomsen
Katelynn Madill-Thomsen
AAArezu Z. Aliabadi-Zuckermann
Arezu Z. Aliabadi-Zuckermann
MCMartin Cadeiras
Martin Cadeiras
MCMarisa G. Crespo-Leiro
Marisa G. Crespo-Leiro
AZAndreas Zuckermann
Andreas Zuckermann
The first-generation Molecular Microscope® (MMDx) system for heart transplant endomyocardial biopsies used expression of rejection-associated transcripts (RATs) to diagnose T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) but also detected acute injury. However, the ideal system should detect rejection without being influenced by injury, to permit analysis of the relationship between rejection and parenchymal injury. To achieve this, we developed a new rejection classification in an expanded cohort of 3230 biopsies: 1641 from INTERHEART (ClinicalTrials.gov #NCT02670408), plus 1589 service biopsies added to improve the power of the machine learning algorithms. The new system used six rejection classifiers instead of RATs and generated seven rejection archetypes: No Rejection 48%; Minor 24%; TCMR1 2.3%; TCMR2 2.7%; TCMR/Mixed 2.7%; EABMR 3.9%; and FABMR 16%. Using rejection classifiers eliminated cross-reactions with acute injury, permitting separate assessment of rejection and injury. TCMR was associated with severe recent injury and late atrophy-fibrosis and rarely had normal parenchyma. ABMR was better tolerated, seldom producing severe injury, but in later biopsies was often associated with atrophy-fibrosis, indicating long term risk. Graft survival and LVEF were reduced in hearts with TCMR, but also in hearts with severe-recent injury and atrophy-fibrosis, even without rejection. INTERHEART: ClinicalTrials.gov NCT02670408.

22 May 2020 in Transplant International
Verified
Journal Article
Open access
PDF file
EOEmilio Osorio-Jaramillo
Emilio Osorio-Jaramillo
GHGeert W. Haasnoot
Geert W. Haasnoot
AKAlexandra Kaider
Alexandra Kaider
ASAnne‐Kristin Schaefer
Anne‐Kristin Schaefer
THThomas Haberl
Thomas Haberl
AAArezu Z. Aliabadi‐Zuckermann
Arezu Z. Aliabadi‐Zuckermann
Background The aim was to evaluate the association of molecular‐level human leukocyte antigen (HLA) mismatching with post‐transplant graft survival, rejection and cardiac allograft vasculopathy (CAV). Methods We retrospectively analysed all primary cardiac transplant recipients between 01/1984‐06/2016. 1,167 patients fulfilled inclusion criteria and had HLA typing information available. In 312 donor‐recipient pairs, typing at serological split antigen level was available. We used the Epitope MisMatch Algorithm to calculate the number of amino acid differences in antibody‐verified HLA eplets (amino acid mismatch‐load (AAMM)) between donor and recipient. Results Patients with a higher HLA‐DR AAMM load had inferior 1‐year graft survival (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.01‐1.28). The HLA‐AB AAMM load showed no impact on graft survival. In the subgroup with available split‐level information, we observed an inferior graft survival for a higher HLA‐DR AAMM load 3 months after transplantation (HR, 1.22; 95% CI, 1.04‐1.44) and a higher risk for rejection for an increasing HLA‐AB (HR, 1.70; 95% CI, 1.29‐2.24) and HLA‐DR (HR, 1.32; 95% CI, 1.09‐1.61) AAMM load. No impact on the development of CAV was found. Conclusions Molecular‐level HLA mismatch analysis could serve as a tool for risk stratification after heart transplantation and might take us one step further into precision medicine.

1 October 2017 in Transplantation Direct
Verified
Journal Article
Open access
JGJohannes Goekler
Johannes Goekler
AZAndreas Zuckermann
Andreas Zuckermann
EOEmilio Osorio-Jaramillo
Emilio Osorio-Jaramillo
FBFaris F. Brkic
Faris F. Brkic
KUKeziban Uyanik-Uenal
Keziban Uyanik-Uenal
AAArezu Aliabadi-Zuckermann
Arezu Aliabadi-Zuckermann
Background: Because of improved long-term survival after heart transplantation (HTx), late graft pathologies such as valvular disease or cardiac allograft vasculopathy (CAV) might need surgical intervention to enhance longer survival and ensure quality of life. To this date, there exist no guidelines for indication of cardiac surgery other than retransplantation after HTx. Methods: In this retrospective, single-center study, we evaluated patients who underwent cardiac surgery after HTx at our institution. Results: Between March 1984 and October 2016, 17 (1.16%) of 1466 HTx patients underwent cardiac surgery other than retransplantation after HTx. Indication were valvular disease (n = 7), CAV (n = 6), and other (n = 4). Of these, 29.4% (n = 5) were emergency procedures and 70.6% were elective cases. Median age at time of surgery was 61 years (interquartile range, 52-66 years); 82.4% (n = 14) were male. Median time to surgery after HTx was 9.3 years (2.7-11.1 years). In-hospital, mortality was 11.8% (n = 2); later need of retransplantation was 11.8% (n = 2) due to progressing CAV 3 to 9 months after surgery. One-year survival was 82.35%; overall survival was 47.1% (n = 8) with a median follow-up of 1477 days (416-2135 days). Overall survival after emergency procedures was 209 days (36-1119.5 days) whereas, for elective procedures, it was 1583.5 days (901.5-4319 days). Conclusions: Incidence of cardiac surgery after HTx in our cohort was low (1.16%) compared with that of other studies. In elective cases, long-term survival was good.

1 May 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PAPhilipp Angleitner
Philipp Angleitner
AKAlexandra Kaider
Alexandra Kaider
JGJohannes Gökler
Johannes Gökler
RMRoxana Moayedifar
Roxana Moayedifar
EOEmilio Osorio-Jaramillo
Emilio Osorio-Jaramillo
AAArezu Aliabadi-Zuckermann
Arezu Aliabadi-Zuckermann

1 August 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AAArezu Z. Aliabadi-Zuckermann
Arezu Z. Aliabadi-Zuckermann
JGJohannes Gökler
Johannes Gökler
AKAlexandra Kaider
Alexandra Kaider
JRJulia Riebandt
Julia Riebandt
RMRoxana Moayedifar
Roxana Moayedifar
AZAndreas Zuckermann
Andreas Zuckermann

26 March 2018 in Transplant International
Verified
Journal Article
Open access
PDF file
JGJohannes Goekler
Johannes Goekler
AZAndreas Zuckermann
Andreas Zuckermann
AKAlexandra Kaider
Alexandra Kaider
PAPhilipp Angleitner
Philipp Angleitner
EOEmilio Osorio-Jaramillo
Emilio Osorio-Jaramillo
AAArezu Z. Aliabadi-Zuckermann
Arezu Z. Aliabadi-Zuckermann
Background Evidence concerning an association between cytomegalovirus (CMV) infection and accelerated cardiac allograft vasculopathy (CAV) is inconclusive. Methods Data were analyzed retrospectively from 297 consecutive heart transplants between 1.1.2002 and 31.12.2012. Patients ≤ 18 years of age, survival and follow‐up ≤ 1‐year post‐transplant and patients with early CAV were excluded. CMV‐infection was diagnosed and monitored closely in the first year. CAV was diagnosed by coronary angiography via left heart catheterization and results were categorized according to the International Society of Heart and Lung Transplantation (ISHLT) scoring system. Risk factors for CAV were tested in a multivariable model. Results Median follow up was 7.5 years (IQR 5.6 – 10.3). CMV infection in the first year after transplantation occurred in 26% of patients (n=78), CMV disease in 5% (n=15). CAV ≥1 ISHLT was detected in 36% (n=108). Incidence of CAV >1 ISHLT and severity of CAV increased over time. No statistically significant association between CMV infection or disease within the first year and risk of CAV after one year post‐HTx was detected in the univariate (p= 0.16) and multivariable (HR, 1.36; CI, 0.89‐2.07; p= 0.16) Cox regression. In the multivariable Cox regression, donor age (hazard ratio (HR), 1.04; 95% confidence interval (CI), 1.02‐1.06; p<0.01) and acute cellular rejection (ACR) ≥ 2R in the first year after HTx (HR, 1.77; 95% CI, 1.06‐2.95; p=0.03) were independent risk factors for CAV development. Conclusion In our cohort, CMV infection and disease in the first year after transplantation did not significantly influence the risk of CAV in the long‐term follow up.